Novo Nordisk A/S (WSE:NVO)
Poland · Delayed Price · Currency is PLN | Market Cap | 656.13B -32.4% |
| Revenue (ttm) | 189.42B +5.6% |
| Net Income | 66.95B +4.8% |
| EPS | 15.06 +5.0% |
| Shares Out | n/a |
| PE Ratio | 9.80 |
| Forward PE | 11.97 |
| Dividend | 6.71 (4.49%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 405 |
| Open | 147.46 |
| Previous Close | 148.80 |
| Day's Range | 146.46 - 149.48 |
| 52-Week Range | 129.26 - 230.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
AbbVie maintains a diversified revenue base by expanding its presence in immunology, neuroscience, and oncology to offset patent cliffs. Novo Nordisk leverages its leadership in the diabetes and obesi...
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the com...
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their we...
Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial
Novo Nordisk (NVO) this week announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, an investigational product, and Novo’s next innovation in weight…
Not Palantir. Not Micron.
Jensen Huang says cybersecurity is the next major use case for artificial intelligence. Cybersecurity is one of the more compute-intensive uses of AI because the inference workloads must run continuou...
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
To see whether Novo Nordisk NYSE: NVO is closing the gap with competitor Eli Lilly NYSE: LLY in the GLP-1 market, investors need only look at patent-cliff timing and current market share. Eli Lilly co...
Novo is open to upgrading its New York listing to boost US profile, FT says
Novo (NVO) is open to upgrading its New York listing to boost its profile in the U.S., following a similar move by AstraZeneca (AZN) earlier in the year, Aanu Adeoye,…
Novo wants to change how Wall Street owns its stock: why now
Novo Nordisk wants a bigger presence on Wall Street, and the timing may say more about the drugmaker's challenges than the listing itself. Chief executive Mike Doustdar said Novo could see advantages ...
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
Novo Nordisk is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Time...
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
Novo Nordisk is in the middle of an important product launch, as it rolls out a pill version of its GLP-1 drug. The company hopes to regain lost market share in the still-emerging GLP-1 weight-loss sp...
Novo Nordisk CEO eyes M&A and a pill-led future after investor backlash
Novo Nordisk CEO Mike Doustdar said the pharmaceutical giant is actively weighing acquisitions to close competitive gaps in the crowded weight-loss drug market, as the Danish drugmaker works to rebuil...
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
Novo Nordisk price target lowered to DKK 245 from DKK 265 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Novo Nordisk (NVO) to DKK 245 from DKK 265 and keeps a Sell rating on the shares.
Novo CEO says pills could capture 50% of weight-loss market by 2030
Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shif...
European drugmakers say they are ‘losing ground’ to US and Chinese rivals
Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard their futures Some of Europe’s biggest pharmaceutical companies have said the continent is “losing gr...
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.
Novo Nordisk and UNICEF renew push to prevent childhood obesity
Novo Nordisk and UNICEF have expanded their partnership to help prevent childhood overweight and obesity, the Danish drugmaker said on Tuesday.
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
The molecule, the active ingredient in both Wegovy and Ozempic, powered the company to unprecedented success. With that, however, investor expectations are high, and it's not hard for those folks to b...
Novo CEO says company needs to increase investor confidence, Bloomberg says
Novo Nordisk (NVO) CEO Mike Doustdar said the company has to do more to increase investor confidence as it faces patent expiration in the U.S. and Europe for Ozempic and…
Novo CEO on M&A: Let's see where the gaps are
Novo CEO Mike Doustdar tells CNBC the drugmaker is mulling M&A opportunities amid increasing competition, and details how the company's units in China and North America are performing.
Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’
Novo shares fell 7.96% to $39.80 on Monday after its growth strategy, disclosed at its Capital Markets Day in London, failed to impress investors In response, Deutsche Bank maintained its Buy rating o...
Novo CEO signals M&A opportunities to strengthen drug pipeline
Novo CEO Mike Doustdar told CNBC it's mulling M&A opportunities amid increasing competition. In this article NVO
Novo Still Has Work to Do to Build Investor Confidence, CEO Says
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopol...
Is Novo Nordisk AS (NVO) a Bargain After 8.0% Drop? GF Value Says Undervalued
Is Novo Nordisk AS (NVO) a Bargain After 8.0% Drop? GF Value Says Undervalued